Cocrystal Pharma, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on October 25, 2022. The Company is a biopharmaceutical entity focused on developing antiviral candidates, with its common stock (COCP) listed on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory compliance and corporate announcements rather than financial performance data.
Material Changes and Events
- Nasdaq Compliance: The Company received notification from Nasdaq on October 25, 2022, confirming compliance with Listing Rule 5550(a)(2). The Company maintained a minimum bid price of at least $1.00 for 10 consecutive business days (October 11 to October 24, 2022), resolving a prior delisting concern.
- Regulation FD Disclosure: On October 26, 2022, the Company issued a press release regarding developments for its orally administered antiviral candidate, CC-42344, intended for the treatment of pandemic and seasonal influenza A.
- Management Presentation: Dr. Sam Lee, President and Co-Interim CEO, was scheduled to present at the LD Micro Main Event XV Conference on October 26, 2022.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or specific risk factors beyond the context of the Nasdaq compliance matter, which is now closed. The press release and presentation materials referenced in Item 7.01 are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference.
Investor Verification Checklist
- Verify the current trading status of COCP on Nasdaq following the compliance confirmation.
- Review the full text of the October 26, 2022 press release (Exhibit 99.1) for specific clinical or commercial details regarding candidate CC-42344.
- Confirm the leadership structure, noting the roles of Dr. Sam Lee and James Martin as Co-Interim CEOs.
- Check subsequent filings for any updated financial statements, as this 8-K does not contain quantitative financial data.